- Departure First of Aprilst, The company’s virtual consultation service allows patients to access clinic services and doctors trained to prescribe medical cannabis
- Teleconsultation service is expected to expand rapidly to meet the potential growing demand for telehealth services, including the company’s 120,000 patients from its ILANS and Zerenia clinics
- Khiron has already received the first approvals from third-party payers to include teleconsultation services in its insured service offerings
- Khiron and its clinics continue to operate during the COVID-19 pandemic under an exemption decreed by the government of Colombia, without other authorization
- Virtual medical services complement Khiron’s delivery service, which already successfully delivers prescriptions directly to patients’ homes
- Acceptance of telemedicine is growing rapidly, with an average growth in visits to the United States of 52% per year from 2005 to 2014 (Source: JAMA)
- Khiron is the first company authorized to sell medical cannabis in Colombia
TORONTO, March 30, 2020 / PRNewswire / – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with basic operations in Latin America, announced today that the company has launched its teleconsultation services, leveraging its medical team and the existing patient network to meet the basic needs of patients during the current COVID-19 pandemic. From an initial beta launch, the company plans to rapidly expand services across its entire patient network amid growing acceptance of telemedicine services.
“We are going through an unprecedented period and it is therefore more important than ever for Khiron to continue to meet the medical needs of our patients. The launch of our teleconsultation services was made possible by our medical expertise and our established patient network, allowing us to act quickly to continue to provide clinical services and prescriptions for medical cannabis and other drugs, directly to patients who need it, “comments Alvaro Torres, CEO and administrator of Khiron.
Khiron teleconsultation services launched on First of Aprilst, with an initial beta phase to meet the priority needs of patients. Expanded services will be launched in the coming weeks to be fully available to patients across Colombia, including the company’s network of over 120,000 patients established through its medical facilities ILANS and Zerenia. The Company works closely with third-party payers to ensure that the program meets their insurance coverage requirements.
“Khiron has emergency plans in place for all of our facilities, including our medical facilities which are essential to serving the community. These plans have been implemented and our medical facilities and our supply chain continue to operate under strict government guidelines established in the wake of the current pandemic. I congratulate our front line staff for their hard work and commitment to meeting the needs of patients during this difficult time, “said Mr. Torres.
Khiron is the first and currently the only company authorized to sell medical cannabis Colombia, having recently obtained the certification of good production practices (GEP) for masterful cannabis preparations. Under Colombian regulations, GEP is a manufacturing and processing certification which is a mandatory requirement for the marketing of personalized medical prescriptions for cannabis called magistral preparations.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the leading integrated medical cannabis company in Latin America. Khiron has basic activities in Latin America, as well as the activity in North America and Europeand is allowed in Colombia for the cultivation, production, domestic distribution and international export of medical cannabis with both tetrahydrocannabinol (THC) and cannabidiol (CBD). The company offers best-in-class regulatory compliance, has the first approved range of off-the-shelf CBD cosmetics in Colombia, and is fully licensed to manufacture medical cannabis with high and low THC content and to fulfill medical cannabis prescriptions at low THC content in the country.
With a targeted regional strategy and patient-focused approach, the company combines global scientific expertise, agricultural benefits, market entry experience for branded products and education to drive prescription and brand loyalty. to treat priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of more than 620 million people. The company is managed by the co-founder and chief executive officer, Alvaro Torres, as well as an experienced management team and a competent board of directors including a former president of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram @khironlife
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained in this document which is not of a historical nature may constitute forward-looking information. Khiron assumes no obligation to comment on analyzes, expectations or declarations made by third parties concerning Khiron, its securities or its financial or operating results (if applicable). Although Khiron believes that the expectations reflected in the forward-looking statements in this press release are reasonable, these forward-looking statements have been based on expectations, factors and assumptions regarding future events which may prove to be inaccurate and are subject to numerous risks and uncertainties. , some of which are outside of Khiron’s control, including the risk factors mentioned in Khiron’s annual information form, which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this warning and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, unless required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The Securities have not been and will not be registered under the United States Securities Act of 1933, as amended (“United States Securities Law”) or state securities laws, and cannot be offered or sold in the United States or to persons in the United States (as this term is defined in Regulation S under the United States Securities Law) unless registered under the United States Securities Law and laws on applicable state securities or an exemption from this listing is available
Neither TSXV nor its regulatory service provider (as that term is defined in TSXV policies) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.